Nanogen sells licenses to Quest Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Molecular diagnostics firm Nanogen will license its proprietary MGB Probe in vitro diagnostic technology to Quest Diagnostics for an undisclosed upfront fee and royalties on tests sold using the licensed technology, Nanogen said March 4. On March 6, the firm reported unaudited 2008 full-year revenues of $46.9 million, up 23%. Fourth-quarter revenues were $9.5 million, down 31% from the previous quarter
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.